14. A. Ferric gluconate 為可經由口服吸收之製劑,生體可用率佳
B. 口服鐵劑時宜與食物併用,可增加吸收,減少胃腸不適的發生
C. 以靜脈注射方式給予iron dextran,可快速被利用於骨髓內
heme 的合成
D. Iron sucrose 之給予劑量為100 mg IV push 至少5 分鐘,其安全
性優於iron dextran
14
97年第1次專技高考 藥物治療學
15. A. 口服元素鐵之劑量由20 mg/day開始
B. 鐵劑宜於空腹時給藥以達最大的吸收率
C. Iron sucrose為最佳之口服鐵補充劑
D. 使用維生素C會減低鐵在胃腸道的吸收
15
99年第2次專技高考 藥物治療學
17. 造成紅血球生成素阻抗之原因
• Iron deficiency
• Hospitalization
• Catheter insertion
• Hypoalbuminemia
• ↑C-reactive protein
• Chronic bleeding
• Aluminum toxicity
• Malnutrition
• Hyperparathyroidism
• Cancer and
chemotherapy
• AIDS
• Inflammation
• Infection
17
18. A. Ferrous sulfate 325 mg TID
B. Ferrous gluconate 325 mg TID with ascorbic acid 500 mg QD
C. Folic acid 1 mg QD
D. Erythropoietin 6000 units/week
18
98年第2次專技高考 藥物治療學
27. New Drugs for Phosphate Binding
• Sevelamer hydrochloride (Renagel®)
▫ ↓PO4, no affecting Ca
▫ ↓ LDL and total cholesterol
▫ Coadministration of Ca
• Lanthanum carbonate (Fosrenol ®)
▫ Accumulation in the bone, liver and brain
▫ Nausea and vomiting
27
28. Vitamin D Therapy
• Active vitamin D suppresses PTH secretion
▫ Ergocalciferol (D2) and cholecalciferol (D3)
▫ Doxercalciferol: 1α (OH) D2
▫ Calcitriol (1,25- dihydroxyvitamin D3)
Most active form of vit. D
• Patients with severe kidney disease
▫ These agents do not require conversion by the kidney
to the biologically active form
28
37. A. Anemia; Calcium gluconate
B. Hyperparathyroidism; Calcitriol
C. Hyperkalemia; Aluminum hydroxide
D. Metabolic acidosis; Ferrous sulfate
37
100年第1次專技高考 藥物治療學